Please assess the completion status of the following clinical trial:

Trial Title: TRIple in asthMA With uncontRolled pAtient on Medium streNgth of ICS + LABA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of asthma ≥ 1 year and diagnosed before 40 years old~* Uncontrolled asthma with double therapy only on medium doses of Inhaled CorticoSteroid (ICS) in combination with Long-acting beta2 Agonist (LABA) with ACQ-7 (Asthma Control Questionnaire) ≥1.5~* Pre-bronchodilator FEV1 \<80% of the predicted normal value~* Positive reversibility test~* At least 1 documented asthma exacerbation in the previous year~Exclusion Criteria:~* Pregnant or lactating women~* Diagnosis of Chronic Obstructive Pulmonary Disease (COPD)~* Patients with any asthma exacerbation or respiratory tract infection in the 4 weeks prior screening~* Current or ex-smokers (\>= 10 packs year)~* Any change in dose, schedule or formulation of ICS + LABA combination in the 4 weeks prior screening

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- CHF 5993 100/6/12.5 µg (Type: EXPERIMENTAL): Treatment A:~CHF 5993 100/6/12.5 µg: 2 inhalations bid Total daily dose: 400/24/50 µg BDP/FF/GB
- CHF 1535 100/6 µg (Type: ACTIVE_COMPARATOR): Treatment B :~CHF 1535 100/6 µg: 2 inhalations bid Total daily dose: 400/24 µg BDP/FF

Based on this trial design, predict the completion outcome and termination type (if applicable).